- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03675464
Study of Human Adipose Tissue (LOSHAT) (LOSHAT)
Longitudinal Observational Study of Human Adipose Tissue (LOSHAT)
연구 개요
상세 설명
The investigators will ask all subjects that have previously been examined at the investigators laboratory (from 1992 and forward) in studies of adipose tissue function if they are interested to participate in a new study.
Previously obtained results from examinations of adipose tissue, anthropometric measurements and blood samples will be used as baseline. In addition, saved blood samples and samples from old fat biopsies can be re-investigated in some cases.
The new investigation includes a questionnaire that the subjects can answer by mail or email. In addition, anthropometric measurements and blood pressure determination will be performed at a primary health care center and blood samples will be collected for analysis of fasting glucose, HbA1C and lipids.
Information regarding all previously investigated subjects will also be collected from several Swedish national patient registries such as the Patient Register, Prescribed Drug register and Cause-of Death register.
연구 유형
등록 (예상)
연락처 및 위치
연구 연락처
- 이름: Peter Arner, MD, PhD
- 전화번호: +468 58582342
- 이메일: peter.arner@ki.se
연구 연락처 백업
- 이름: Daniel P Andersson, MD, PhD
- 전화번호: +468 58580000
- 이메일: daniel.p.andersson@ki.se
연구 장소
-
-
-
Stockholm, 스웨덴, 14186
- 모병
- Karolinska University Hospital
-
연락하다:
- Daniel P Andersson, MD, PhD
- 이메일: daniel.p.andersson@ki.se
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Previously participated in examinations at the investigators laboratory and donated adipose tissue.
- Previously participated in examinations at the investigators laboratory and donated blood samples that can be used to estimate lipolysis with a formula.
Exclusion Criteria:
- Decline to participate after invitation.
- Severe Psychiatric disease.
- Type 1 Diabetes
- Participants that have undergone bariatric surgery will be exluded in the primary analysis but will be analyzed separately in a secondary analysis for all above mentioned outcomes.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Body mass index
기간: 2018 to 2022
|
Body weight (in kilogram) will be assessed with a regular scale.
Height will be measured with a tape measure (in centimeters).
Body mass index (BMI) will be calculated with the formula weight (kg) divided by height^2 (in meter).
Changes in BMI from baseline values will be analysed.
|
2018 to 2022
|
|
Fasting glucose
기간: 2018 to 2022
|
Fasting plasma glucose will be assessed and divided into normal glucose (glucose < 6.1 mmol/L), impaired fasting glucose (glucose 6.1-6.9 mmol/L) or type 2 diabetes (glucose > 6.9 mmol/L).
|
2018 to 2022
|
|
Number of participants with metabolic syndrome
기간: 2018 to 2022
|
Metabolic syndrome is defined according to International Diabetes Federation, Waist circumference ≥102 cm for men or ≥88 cm for women.
In addition to this 2 of the following; Raised triglycerides: > 150 mg/dL (1.7 mmol/L), or specific treatment for this lipid abnormality; Reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in males, < 50 mg/dL (1.29 mmol/L) in females, or specific treatment for this lipid abnormality; Raised blood pressure (BP): systolic BP > 130 or diastolic BP >85 mm Hg, or treatment of previously diagnosed hypertension; Raised fasting plasma glucose (FPG): >100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 diabetes.
Scores are 0-5.
≥ 3 is defined as metabolic syndrome.
|
2018 to 2022
|
|
Number of participants with type 2 Diabetes
기간: 2018 to 2022
|
Based on a diagnosis in the Swedish National Patient Register, or prescribed drugs for Type 2 diabetes in the Swedish National Prescribed Drug Register or direct information from the subject.
|
2018 to 2022
|
|
Number of participants with dyslipidemia
기간: 2018 to 2022
|
Based on a diagnosis in the Swedish National Patient Register, or prescribed drugs for dyslipidemia in the Swedish National Prescribed Drug Register, or direct information from the subject.
|
2018 to 2022
|
|
Number of participants with Hypertension
기간: 2018 to 2022
|
Based on a diagnosis in the Swedish National Patient Register, or prescribed drugs for hypertension in the Swedish National Prescribed Drug Register, or direct information from the subject.
|
2018 to 2022
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Genetic variations linked to lipolysis
기간: 2018 to 2022
|
Genome-wide association study (GWAS) with focus on genes related to lipolysis and analysis of single nucleotide polymorphisms (SNPs).
Samples from baseline examination will be used in the analysis.
|
2018 to 2022
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Peter Arner, MD, PhD, Karolinska University Hospital
- 연구 책임자: Daniel P Andersson, MD, PhD, Karolinska University Hospital
- 연구 의자: Mikael Rydén, Md, PhD, Karolinska University Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .